D
DIAREN UG (HAFTUNGSBESCHRÄNKT)
Die Nieren übernehmen lebenswichtige Funktionen der Entgiftung in unserem Körper. Ein chronisches Nierenleiden verläuft oft lange Zeit völlig unbemerkt, da ...
Country/Area ：Germany
Company Email ：info@diaren.de
Company address ：Homburg
Company website ：*****
Established ：-
Number of employees ：4
Web Summary
Q1: What is the company name and its type?
A1: The company name is DiaRen UG (haftungsbeschränkt), which translates to "DiaRen Limited Liability Company" in English. It appears to be a medical device company, specifically focused on developing innovative biomarkers for early diagnosis of kidney diseases.
Q2: What is the product offered by DiaRen?
A2: The product offered by DiaRen is ReFiNE, a test that enables the early detection of kidney damage using the biomarker Dkk3. This test is designed to be non-invasive and can be performed on urine samples.
Q3: What is the purpose of the ReFiNE test?
A3: The purpose of the ReFiNE test is to enable the early diagnosis of kidney damage, allowing for timely intervention and potential treatment to slow down the progression of the disease. It also helps in monitoring the effectiveness of therapeutic measures such as blood pressure reduction or pharmacological interventions.
Q4: What is Dkk3 and its significance?
A4: Dkk3 (Dickkopf-3) is a biomarker that has been identified as a potential indicator of kidney damage. Its concentration in urine can predict the progression of kidney disease, making it a valuable tool for early diagnosis and monitoring.
Q5: What is the prevalence of chronic kidney disease (CKD) in Germany?
A5: According to data from 2016, approximately 2.3% of adults between 18 and 79 years old have a reduced glomerular filtration rate (GFR), indicating CKD. This translates to around 2 million people in the general population.
Q6: What is the significance of early diagnosis of kidney disease?
A6: Early diagnosis of kidney disease can lead to timely intervention, which may slow down the progression of the disease and potentially improve outcomes for patients. However, many cases of CKD remain undiagnosed due to the lack of symptoms, highlighting the importance of screening tests like ReFiNE.
Q7: What is the address of DiaRen's headquarters?
A7: The address of DiaRen UG (haftungsbeschränkt) is Universitätsklinikum Starterzentrum Gebäude 7, 66424 Homburg.
Q8: How can one contact DiaRen for further information or inquiries?
A8: One can contact DiaRen by sending an email to info@diaren.de or by filling out the contact form on their website.
A1: The company name is DiaRen UG (haftungsbeschränkt), which translates to "DiaRen Limited Liability Company" in English. It appears to be a medical device company, specifically focused on developing innovative biomarkers for early diagnosis of kidney diseases.
Q2: What is the product offered by DiaRen?
A2: The product offered by DiaRen is ReFiNE, a test that enables the early detection of kidney damage using the biomarker Dkk3. This test is designed to be non-invasive and can be performed on urine samples.
Q3: What is the purpose of the ReFiNE test?
A3: The purpose of the ReFiNE test is to enable the early diagnosis of kidney damage, allowing for timely intervention and potential treatment to slow down the progression of the disease. It also helps in monitoring the effectiveness of therapeutic measures such as blood pressure reduction or pharmacological interventions.
Q4: What is Dkk3 and its significance?
A4: Dkk3 (Dickkopf-3) is a biomarker that has been identified as a potential indicator of kidney damage. Its concentration in urine can predict the progression of kidney disease, making it a valuable tool for early diagnosis and monitoring.
Q5: What is the prevalence of chronic kidney disease (CKD) in Germany?
A5: According to data from 2016, approximately 2.3% of adults between 18 and 79 years old have a reduced glomerular filtration rate (GFR), indicating CKD. This translates to around 2 million people in the general population.
Q6: What is the significance of early diagnosis of kidney disease?
A6: Early diagnosis of kidney disease can lead to timely intervention, which may slow down the progression of the disease and potentially improve outcomes for patients. However, many cases of CKD remain undiagnosed due to the lack of symptoms, highlighting the importance of screening tests like ReFiNE.
Q7: What is the address of DiaRen's headquarters?
A7: The address of DiaRen UG (haftungsbeschränkt) is Universitätsklinikum Starterzentrum Gebäude 7, 66424 Homburg.
Q8: How can one contact DiaRen for further information or inquiries?
A8: One can contact DiaRen by sending an email to info@diaren.de or by filling out the contact form on their website.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
